$ISCO
International Stem Cell CORP Stock $isco

$isco Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000156459022037618 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$2.430M	$1.703M	$1.842M
YoY Change	31.85%	-7.55%	24.38%
Cost Of Revenue	$1.136M	$690.0K	$814.0K
YoY Change	54.56%	-15.23%	44.58%
Gross Profit	$1.294M	$1.013M	$1.028M
YoY Change	16.79%	-1.46%	11.98%
Gross Profit Margin	53.25%	59.48%	55.81%
Selling, General & Admin	$1.108M	$1.166M	$1.486M
YoY Change	-9.77%	-21.53%	1.71%
% of Gross Profit	85.63%	115.1%	144.55%
Research & Development	$125.0K	$147.0K	$165.0K
YoY Change	-38.42%	-10.91%	-35.29%
% of Gross Profit	9.66%	14.51%	16.05%
Depreciation & Amortization	$52.00K	$55.00K	$65.00K
YoY Change	-22.39%	-15.38%	1.56%
% of Gross Profit	4.02%	5.43%	6.32%
Operating Expenses	$1.233M	$1.313M	$1.651M
YoY Change	-13.84%	-20.47%	-3.79%
Operating Profit	$61.00K	-$300.0K	-$623.0K
YoY Change	-118.89%	-51.85%	-21.93%
Interest Expense	-$33.00K	-$35.00K	-$18.00K
YoY Change	-19.51%	94.44%	-164.29%
% of Operating Profit	-54.1%
Other Income/Expense, Net	-$5.000K	-$43.00K	$458.0K
YoY Change	-138.46%	-109.39%
Pretax Income	$23.00K	-$343.0K	-$165.0K
YoY Change	-106.55%	107.88%	-69.67%
Income Tax
% Of Pretax Income
Net Earnings	$23.00K	-$343.0K	-$165.0K
YoY Change	-106.55%	107.88%	-69.67%
Net Earnings / Revenue	0.95%	-20.14%	-8.96%
Basic Earnings Per Share		-$0.04	-$0.02
Diluted Earnings Per Share	$0.00	-$0.04	-$20.61K
COMMON SHARES
Basic Shares Outstanding	8.004M	8.004M	8.004M
Diluted Shares Outstanding		8.004M	8.004M

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$742.0K	$666.0K	$505.0K
YoY Change	333.92%	31.88%	-50.78%
Cash & Equivalents	$742.0K	$666.0K	$505.0K
Short-Term Investments
Other Short-Term Assets	$90.00K	$53.00K	$174.0K
YoY Change	429.41%	-69.54%	9.43%
Inventory	$1.384M	$1.415M	$1.139M
Prepaid Expenses	$64.00K
Receivables	$747.0K	$427.0K	$668.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.963M	$2.700M	$2.486M
YoY Change	26.95%	8.61%	-5.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$248.0K	$279.0K	$419.0K
YoY Change	-35.42%	-33.41%	-72.2%
Goodwill
YoY Change
Intangibles	$878.0K	$896.0K
YoY Change	-7.48%
Long-Term Investments
YoY Change
Other Assets	$319.0K	$403.0K	$411.0K
YoY Change	-22.38%	-1.95%	-8.05%
Total Long-Term Assets	$2.172M	$2.342M	$2.451M
YoY Change	-16.85%	-4.45%	-23.88%
TOTAL ASSETS
Total Short-Term Assets	$2.963M	$2.700M	$2.486M
Total Long-Term Assets	$2.172M	$2.342M	$2.451M
Total Assets	$5.135M	$5.042M	$4.937M
YoY Change	3.82%	2.13%	-15.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$322.0K	$378.0K	$611.0K
YoY Change	-36.61%	-38.13%	56.27%
Accrued Expenses	$508.0K	$475.0K	$576.0K
YoY Change	25.74%	-17.53%	-18.41%
Deferred Revenue
YoY Change
Short-Term Debt	$3.325M	$3.291M	$2.912M
YoY Change	12.98%	13.02%	18.95%
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$4.635M	$4.613M	$4.349M
YoY Change	8.19%	6.07%	12.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$720.0K	$781.0K	$645.0K
YoY Change	-24.21%	21.09%	-33.91%
Total Long-Term Liabilities	$720.0K	$781.0K	$645.0K
YoY Change	-24.21%	21.09%	-59.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.635M	$4.613M	$4.349M
Total Long-Term Liabilities	$720.0K	$781.0K	$645.0K
Total Liabilities	$5.355M	$5.394M	$4.994M
YoY Change	2.31%	8.01%	-7.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.3M	-$110.4M	-$109.7M
YoY Change	0.26%	0.64%	1.2%
Common Stock	$8.000K	$8.000K	$8.000K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.520M	-$4.652M	-$4.357M
YoY Change
Total Liabilities & Shareholders Equity	$5.135M	$5.042M	$4.937M
YoY Change	3.82%	2.13%	-15.62%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	$23.00K	-$343.0K	-$165.0K
YoY Change	-106.55%	107.88%	-69.67%
Depreciation, Depletion And Amortization	$52.00K	$55.00K	$65.00K
YoY Change	-22.39%	-15.38%	1.56%
Cash From Operating Activities	$79.00K	$84.00K	-$224.0K
YoY Change	-125.0%	-137.5%	-19.13%
INVESTING ACTIVITIES
Capital Expenditures	$3.000K	-$4.000K	-$21.00K
YoY Change	-116.67%	-80.95%	75.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$3.000K	-$4.000K	-$21.00K
YoY Change	-83.33%	-80.95%	75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	79.00K	84.00K	-224.0K
Cash From Investing Activities	-3.000K	-4.000K	-21.00K
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	76.00K	80.00K	-245.0K
YoY Change	-122.75%	-132.65%	-15.22%
FREE CASH FLOW
Cash From Operating Activities	$79.00K	$84.00K	-$224.0K
Capital Expenditures	$3.000K	-$4.000K	-$21.00K
Free Cash Flow	$76.00K	$88.00K	-$203.0K
YoY Change	-125.5%	-143.35%	-23.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001355790
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	384000
CY2022Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	369000
CY2022Q3	us-gaap	Inventory Net InventoryNet	1415000
CY2021Q4	us-gaap	Inventory Net InventoryNet	1184000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	279000
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8004389
CY2021Q4	us-gaap	Cash Cash	171000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	179000
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	949000
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	378000
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	475000
CY2021Q4	isco	Advances From Nonaffiliated Collaboration AdvancesFromNonaffiliatedCollaboration	250000
CY2022Q3	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	3291000
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2229000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-4506000
	us-gaap	Operating Lease Cost OperatingLeaseCost	355000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5750000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5333000
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2021Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M15D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M15D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M1D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M1D
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-51891
	dei	Entity Registrant Name EntityRegistrantName	INTERNATIONAL STEM CELL CORPORATION
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4494098
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5950 Priestly Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Carlsbad
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92008
	dei	City Area Code CityAreaCode	760
	dei	Local Phone Number LocalPhoneNumber	940-6383
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	us-gaap	Cash Cash	666000
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	427000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	844000
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	192000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	135000
CY2022Q3	us-gaap	Assets Current AssetsCurrent	2700000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	2334000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	372000
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	896000
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	764000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	868000
CY2022Q3	isco	Deposits And Other Assets DepositsAndOtherAssets	34000
CY2021Q4	isco	Deposits And Other Assets DepositsAndOtherAssets	39000
CY2022Q3	us-gaap	Assets Assets	5042000
CY2021Q4	us-gaap	Assets Assets	4946000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	508000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	404000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	219000
CY2022Q3	isco	Advances From Nonaffiliated Collaboration AdvancesFromNonaffiliatedCollaboration	250000
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	2943000
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4613000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4284000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	781000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	950000
CY2022Q3	us-gaap	Liabilities Liabilities	5394000
CY2021Q4	us-gaap	Liabilities Liabilities	5234000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8004389
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8004389
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8004389
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8004389
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	8000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	105703000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	105413000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110368000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110014000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4588000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4652000
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5042000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4946000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1703000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1842000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5750000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5333000
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	690000
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	814000
	us-gaap	Cost Of Revenue CostOfRevenue	2133000
	us-gaap	Cost Of Revenue CostOfRevenue	2200000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	147000
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	165000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	367000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	492000
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	358000
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	352000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	982000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1049000
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	808000
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1134000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2512000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3190000
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	2003000
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	2465000
	us-gaap	Costs And Expenses CostsAndExpenses	5994000
	us-gaap	Costs And Expenses CostsAndExpenses	6931000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-300000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-623000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-244000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1598000
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	476000
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1137000
CY2022Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	33000
CY2021Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	30000
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	98000
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	87000
CY2022Q3	isco	Interest Expense Related Party Including Other Miscellaneous InterestExpenseRelatedPartyIncludingOtherMiscellaneous	35000
CY2021Q3	isco	Interest Expense Related Party Including Other Miscellaneous InterestExpenseRelatedPartyIncludingOtherMiscellaneous	31000
	isco	Interest Expense Related Party Including Other Miscellaneous InterestExpenseRelatedPartyIncludingOtherMiscellaneous	102000
	isco	Interest Expense Related Party Including Other Miscellaneous InterestExpenseRelatedPartyIncludingOtherMiscellaneous	97000
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10000
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43000
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	458000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-110000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1050000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-343000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-165000
	us-gaap	Net Income Loss NetIncomeLoss	-354000
	us-gaap	Net Income Loss NetIncomeLoss	-548000
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004000
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004000
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7772000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7772000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4588000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	91000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-9000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	90000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-4418000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	109000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-343000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4652000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-4333000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	234000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-599000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-4698000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	172000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	216000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-4310000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	118000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-165000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-4357000
	us-gaap	Profit Loss ProfitLoss	-354000
	us-gaap	Profit Loss ProfitLoss	-548000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	166000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	195000
	isco	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	104000
	isco	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	215000
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	250000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-4000
	us-gaap	Share Based Compensation ShareBasedCompensation	290000
	us-gaap	Share Based Compensation ShareBasedCompensation	524000
	isco	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt	1137000
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	98000
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	87000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-417000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	265000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	228000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	216000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	57000
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-5000
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-17000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-130000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	251000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	71000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-104000
	isco	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-129000
	isco	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-254000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	253000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-981000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	14000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27000
	isco	Proceeds From Paycheck Protection Program Loan Amount ProceedsFromPaycheckProtectionProgramLoanAmount	474000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	350000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	250000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	824000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	495000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-184000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	689000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	666000
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	505000
	isco	Gain On Forgiveness Of Debt GainOnForgivenessOfDebt	1137000
	isco	Patent License Costs Included In Accrued Liabilities PatentLicenseCostsIncludedInAccruedLiabilities	7000
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110400000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, and the fair value of stock option grants using the Black-Scholes option valuation model. By their nature, estimates are subject to an inherent degree of uncertainty and actual results could differ from these estimates.</p>
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the biomedical market (LCT) and anti-aging market (LSC). The biomedical market sells primary human cell research products with two product categories, cells and media, which are sold both domestically and internationally. The biomedical market also offers performance of quality control (QC) testing services. No revenue from services was earned during the three and nine months ended September 30, 2022 and 2021. Prior to January 1, 2022, the anti-aging market sold skincare products through two sales channels: ecommerce and professional. The ecommerce channel sold directly to customers through online orders, while professional sales were primarily to spas, salons, and other skincare providers. As of January 1, 2022, the anti-aging market sells products solely through the ecommerce channel. As such, there was no revenue earned pertaining to the professional channel for skin care during the three and nine months ended September 30, 2022.
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2022Q3	isco	Number Of Products Categories NumberOfProductsCategories	2
	isco	Number Of Sales Channels NumberOfSalesChannels	2
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	427000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	844000
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
	isco	Reduction In Research And Development Expenses ReductionInResearchAndDevelopmentExpenses	80000
	isco	Reduction In Research And Development Expenses ReductionInResearchAndDevelopmentExpenses	113000
CY2022Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0
CY2022Q3	isco	Financial Assets Fair Value Disclosure FinancialAssetsFairValueDisclosure	0
CY2021Q4	isco	Financial Assets Fair Value Disclosure FinancialAssetsFairValueDisclosure	0
CY2021Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	0
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12935014
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12935014
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11107151
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11107151
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Customer Concentrations<span style="font-weight:normal;font-style:normal;"> </span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30, 2022 and 2021, one customer accounted for approximately 43% and 38% of consolidated revenues, respectively. As of September 30, 2022 and December 31, 2021, the customer accounted for approximately 35% and 62%, respectively, of accounts receivable, net. No other single customer accounted for more than 10% of revenues for the periods then ended for any segment. </p>
CY2022Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	697000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	592000
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	553000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	507000
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1129000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	983000
CY2022Q3	us-gaap	Inventory Gross InventoryGross	2379000
CY2021Q4	us-gaap	Inventory Gross InventoryGross	2082000
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	595000
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	526000
CY2022Q3	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1784000
CY2021Q4	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1556000
CY2022Q3	us-gaap	Inventory Net InventoryNet	1415000
CY2021Q4	us-gaap	Inventory Net InventoryNet	1184000
CY2022Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	369000
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	372000
CY2022Q3	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1784000
CY2021Q4	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1556000
CY2022Q3	isco	Prepaid Assets Current PrepaidAssetsCurrent	139000
CY2021Q4	isco	Prepaid Assets Current PrepaidAssetsCurrent	118000
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	53000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	17000
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	192000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	135000
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2508000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2507000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2123000
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	279000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	384000
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34000
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	41000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	106000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	124000
CY2022Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1284000
CY2021Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1277000
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	463000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	403000
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	821000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	874000
CY2022Q3	isco	Indefinite Life Logos And Trademarks IndefiniteLifeLogosAndTrademarks	75000
CY2021Q4	isco	Indefinite Life Logos And Trademarks IndefiniteLifeLogosAndTrademarks	75000
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	896000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	949000
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21000
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	24000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	60000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	71000
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0
CY2022Q3	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	1
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	290000
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0286
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0286
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0089
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0089
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9029
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9029
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8385
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8385
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	109000
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	118000
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	693000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M4D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	524000
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15609580
CY2021Q4	isco	Lease Costs Incurred Percentage LeaseCostsIncurredPercentage	0.40
	isco	Number Of Operating Leases NumberOfOperatingLeases	3
CY2021Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2026-12-31
CY2021Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	11000
CY2021Q4	isco	Percentage Of Increase Rent Per Annum Over Lease Term PercentageOfIncreaseRentPerAnnumOverLeaseTerm	0.035
CY2021Q4	isco	Percentage Of Base Rent Abated PercentageOfBaseRentAbated	0.50
CY2021Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2026-12-31
CY2021Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	4000
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	71000
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	118000
	us-gaap	Operating Lease Cost OperatingLeaseCost	213000
CY2022Q3	isco	Finance Leases FinanceLeases	0
CY2021Q4	isco	Finance Leases FinanceLeases	0
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	82000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	338000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	349000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	360000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	119000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1248000
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	248000
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1000000
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	219000
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	781000
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3
	isco	Number Of Business Units NumberOfBusinessUnits	2
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1703000
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1842000
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	2003000
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	2465000
	us-gaap	Costs And Expenses CostsAndExpenses	5994000
	us-gaap	Costs And Expenses CostsAndExpenses	6931000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-300000
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-623000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-244000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1598000

Files In Submission

Name	View Source	Status
0001564590-22-037618-index-headers.html	Edgar Link	pending
0001564590-22-037618-index.html	Edgar Link	pending
0001564590-22-037618.txt	Edgar Link	pending
0001564590-22-037618-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
isco-10q_20220930.htm	Edgar Link	pending
isco-20220930.xsd	Edgar Link	pending
isco-ex311_8.htm	Edgar Link	pending
isco-ex312_9.htm	Edgar Link	pending
isco-ex321_6.htm	Edgar Link	pending
isco-ex322_7.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
isco-10q_20220930_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
isco-20220930_cal.xml	Edgar Link	unprocessable
isco-20220930_def.xml	Edgar Link	unprocessable
isco-20220930_lab.xml	Edgar Link	unprocessable
isco-20220930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ISCO
International Stem Cell CORP Stock $isco

2022 Q4 Form 10-Q Financial Statement

#000156459022037618 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ISCO International Stem Cell CORP Stock $isco

2022 Q4 Form 10-Q Financial Statement

#000156459022037618 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ISCO
International Stem Cell CORP Stock $isco